๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Huai'an
Clinical trial register · China

Clinical Trials in Huai'an, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Huai'an First People's Hospital3 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School3 Second Affiliated Hospital of Soochow University2 Chongqing Claruvis Pharmaceutical Co., Ltd.2 AstraZeneca2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Huai'an

39 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Frontal vs Parietal Eminence Drainage for Chronic Subdural Hematoma
NCT07731620Chronic Subdural Hematoma
The Second Hospital of Anhui Medical University
Not applicable
440
Hefei, Huai'an, Yangzhou
2027-01
Recruiting
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease
NCT07764094PCI, Drug-coated Balloon, Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Observational
500
Chuzhou, Tongling, Huai'an, Lianyungang, Nanjing, Xuzhou, Yixing
2026-09-01
Not yet open
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
NCT07764601Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
WEI XU
Not applicable
58
Changzhou, Huai'an, Nanjing, Wuxi, Yixing
2026-08
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
600
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-08
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
1,200
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-06
Recruiting
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
NCT07670416Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
Hoffmann-La Roche
Phase 3
300
Zhengzhou, Xianyang, Ningbo, Beijing, Changchun, Hefei, Herbin, Huai'an
2026-07-03
Recruiting
Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
NCT07673640Non-Segmental Vitiligo (NSV)
ShanShan Li
Observational
300
Shenzhen, Huai'an, Suzhou, Xuzhou, Dongying, Shanghai, Changzhou, Jiaozuo
2026-07-02
By invitation
Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
NCT07658417Diabetes Mellitus, Type 2
Novo Nordisk A/S
Observational
216
Beijing, Chongqing, Lanzhou, Jiangmen, Langfang, Harbin, Shiyan, Huai'an
2026-07-02
Recruiting
A Study of Metformin to Improve Cardiac Function After LVAD Implantation
NCT07666698Heart Failure, Left Ventricular Assist Device
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2
108
Nanjing, Hangzhou, Haโ€™erbin, Huai'an, Zhengzhou
2026-07-01
Not yet open
A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance
NCT07622550Metastatic Colorectal Cancer (CRC)
Jiangsu Cancer Institute & Hospital
Phase 2
80
Changzhou, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Wuxi, Xuzhou
2026-06-15
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
644
Beijing, Changzhou, Chongqing, Guangzhou, Huai'an, Ningbo, Shijiazhuang, Zhuzhou
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
Janssen Research & Development, LLC
Phase 3
460
Beijing, Changzhou, Chongqing, Guangzhou, Hangzhou, Huai'an, Ningbo, Zhuzhou
2026-05-22
Active, closed
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
NCT07663903Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Ganzhou, Guangzhou, Hefei, Huai'an, Jinan
2026-04-14
Recruiting
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
NCT07478822Upper Limb Spasticity
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 3
300
Beijing, Chengdu, Guangdong, Guangzhou, Hefei, Huai'an, Kaifeng, Kunming
2026-03-27
Not yet open
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
NCT07486479Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University
Phase 3
204
Hefei, Luoyang, Wuhan, Changzhou, Huai'an, Jingjiang, Lianyungang, Nanjing
2026-03-10
Not yet open
Comparison of Radiofrequency Ablation With Concomitant or Staged Treatment for Tributary Varicose Veins
NCT07445425Varicose Veins of Lower Limb
Sir Run Run Shaw Hospital
Not applicable
206
Bengbu, Beijing, Nanning, Haikou, Zhengzhou, Zhoukou, Chenzhou, Huai'an
2026-03
Not yet open
Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes
NCT07063797Type 2 Diabetes, Osteoporosis, Fractures
Peking Union Medical College Hospital
Not applicable
358
Beijing, Huai'an, Jiangxi, Kunshan
2026-02-01
Recruiting
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .
NCT07242300Upper Limb Spasticity (ULS)
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
207
Beijing, Shijiazhuang, Luoyang, Zhengzhou, Changsha, Huai'an, Suzhou, Pingxiang
2025-12-11
Not yet open
Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
NCT06683131Acute Myocardial Infarction (AMI)
The Affiliated Hospital of Xuzhou Medical University
Phase 4
1,160
Fuyang, Huai'an, Lianyungang, Nanjing, Suqian, Xuzhou, Beijing, Shanghai
2025-11-20
Recruiting
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
NCT07805967Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Second Affiliated Hospital of Soochow University
Observational
500
Changshu, Huai'an, Kunshan, Nanjing, Nantong, Suqian, Suzhou, Xuzhou
2025-11-12
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naรฏve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,000
Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an
2025-09-28
Recruiting
Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
NCT07095790Mild Stroke
Second Affiliated Hospital of Soochow University
Phase 4
580
Suzhou, Shijiazhuang, Zhoukou, Bayan Nur, Huai'an, Suqian, Taizhou, Xi'an
2025-08-30
Recruiting
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
Atom Therapeutics Co., Ltd
Phase 2
380
Beijing, Nanning, Langfang, Wuhan, Xiangtan, Zhuzhou, Huai'an, Pingxiang
2025-08-26
By invitation
A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer
NCT06936488MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients
Huai'an First People's Hospital
Not applicable
35
Huai'an
2025-03-01
Recruiting
A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)
NCT05230914Stroke, Ischemic, Stroke, Acute
Xinqiao Hospital of Chongqing
Not applicable
1,846
Wuhu, Chongqing, Jiangmen, Haikou, Huai'an, Wuxi, Jingdezhen, Dalian
2024-12-12
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
argenx
Phase 3
69
Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan
2024-10-18
Recruiting
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
NCT06783114Upper Limb Spasticity
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 2/3
254
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an
2024-09-14
Recruiting
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
NCT06566807Marginal Zone Lymphoma
Huai'an First People's Hospital
Phase 2
51
Huai'an
2024-08-25
Recruiting
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031Crohn Disease, Stricture; Bowel, Intestinal Stricture
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
239
Beijing, Chongqing, Guangzhou, Huai'an, Suzhou, Yangzhou, Hangzhou
2024-08-01
Recruiting
Goal-directed Enteral Nutritional Perioperative Management
NCT06510543Esophagus Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
400
Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan
2024-03-30
Recruiting
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
NCT06051513Carbapenem-Resistant Enterobacteriaceae Infection
Southeast University, China
Not applicable
404
Hefei, Jinjiang, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Taizhou
2023-11-27
Recruiting
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
NCT05881265APL
Shanghai Jiao Tong University School of Medicine
Phase 2
30
Huai'an, Nanchang, Shanghai, Guangzhou
2023-05-15
Recruiting
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
NCT05686642Acute Ischemic Stroke
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
300
Beijing, Guangzhou, Luoyang, Hengshui, Daqing, Wuhan, Baotou, Huai'an
2023-04-06
Recruiting
Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
NCT05661786Chronic Hepatitis b
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
4,500
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2022-12
Recruiting
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
NCT06328179Acute Myeloid Leukemia
Huai'an First People's Hospital
Not applicable
34
Huai'an
2022-05-24
Recruiting
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
NCT06536010Acute Myeloid Leukemia
Yang Xiaotian
Not applicable
50
Huai'an
2021-11-03
Active, closed
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site, Genital Neoplasms, Female
Wenjun Cheng
Phase 2
56
Huai'an, Nanjing, Suzhou, Wuxi, Yancheng
2021-08-24
Recruiting
"Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu
NCT03097952Hepatitis B๏ผŒ Chronic
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
20,000
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2008-01
Rows per page Showing 1–39 of 39
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/huai-an

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 39 of those studies with a site in Huai'an.

How many clinical trials are recruiting in Huai'an?

28 of the 39 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 2 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Huai'an), 39 studies
PhaseStudiesRecruitingShare
Phase 311928.2%
Not applicable10525.6%
Observational7617.9%
Phase 26415.4%
Phase 1/2225.1%
Phase 4215.1%
Phase 2/3112.6%

Most active sponsors

Lead sponsors with the most studies (Huai'an)
Lead sponsorStudiesRecruiting
Huai'an First People's Hospital32
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School33
AstraZeneca22
Chongqing Claruvis Pharmaceutical Co., Ltd.22
Janssen Research & Development, LLC22
Second Affiliated Hospital of Soochow University22
argenx11
Atom Therapeutics Co., Ltd11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences11
Hangzhou Gensciences Biopharmaceutical Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.